Julie Hambleton
Directeur/Bestuurslid bij IGM BIOSCIENCES, INC.
Vermogen: 413 021 $ op 30-04-2024
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Akshay Nanduri | M | - |
Onc.ai, Inc.
Onc.ai, Inc. Packaged SoftwareTechnology Services Onc.ai, Inc. is a digital health company that is privately held and is developing a precision oncology care management platform. The company is based in San Carlos, CA. The company aims to transform clinical decision making and is backed by premier investment firms such as the Blue Venture Fund, MassMutual Alternative Investments, and Accomplice, among others. The company is building a pipeline of physician-centered products to fulfill the potential of precision oncology. The company was founded by Akshay Nanduri, who has been the CEO since incorporation. | - |
Fred Schwarzer | M | 72 | 21 jaar | |
Michael Varney | M | 65 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 19 jaar |
Daniel Lynch | M | 65 | 8 jaar | |
Jonathan Lim | M | 52 | 6 jaar | |
Saqib Islam | M | 54 | 7 jaar | |
Felix Baker | M | 55 | 3 jaar | |
Thomas Hawes | M | 48 |
Onc.ai, Inc.
Onc.ai, Inc. Packaged SoftwareTechnology Services Onc.ai, Inc. is a digital health company that is privately held and is developing a precision oncology care management platform. The company is based in San Carlos, CA. The company aims to transform clinical decision making and is backed by premier investment firms such as the Blue Venture Fund, MassMutual Alternative Investments, and Accomplice, among others. The company is building a pipeline of physician-centered products to fulfill the potential of precision oncology. The company was founded by Akshay Nanduri, who has been the CEO since incorporation. | - |
Bruce Turner | M | 60 |
Gennao Bio, Inc.
Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021. | 4 jaar |
Jean Liu | F | 55 | 2 jaar | |
Jakob Haldor Topsøe | M | 55 | 6 jaar | |
Robert Shoemaker | M | 43 | 6 jaar | |
Christina Teng Topsøe | F | 43 | 6 jaar | |
William Strohl | M | 71 | 6 jaar | |
Chandra D. Lovejoy | F | 52 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 3 jaar |
Badreddin Edris | M | 37 | 6 jaar | |
Valerie Start | M | 64 | 5 jaar | |
Scott Morrison | M | 66 | 6 jaar | |
Christopher M. Duke | M | 52 |
Gennao Bio, Inc.
Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021. | 3 jaar |
Elizabeth Thompson | M | 49 | 1 jaar | |
David Chacko | M | 41 | 5 jaar | |
Kim Diamond | F | - | 6 jaar | |
T. S. Harigopal | M | - | 3 jaar | |
Michael Lee | M | 45 | 5 jaar | |
Jason Throne | M | 53 | 5 jaar | |
Pratik Multani | M | 57 | 6 jaar | |
Alexander Casdin | M | 56 | 6 jaar | |
Alan Fuhrman | M | 67 | 5 jaar | |
Herschel Weinstein | M | 68 | 4 jaar | |
Freda Lewis-Hall | M | 69 | 7 jaar | |
Carlos Alban | M | 61 | 2 jaar | |
M. Wilsey | M | 71 | 5 jaar | |
Theodore Samuels | M | 69 | 7 jaar | |
Wendy Yarno | F | 68 | 5 jaar | |
Ebun Garner | M | 52 | 3 jaar | |
James Cassidy | M | 65 | 7 jaar | |
James Bristol | M | 77 | 6 jaar | |
Paul A. Barsanti | M | - | 5 jaar | |
Brain Baker | M | - | - | |
Les Brail | M | - | - | |
Rachel Cervantes | F | - | - | |
Nik Chetwyn | M | - | 3 jaar | |
Mindy Goldman | F | - |
The University of California, San Francisco
| 31 jaar |
Angus M. Sinclair | M | - | 6 jaar | |
Shannon Morris | M | 54 | 2 jaar | |
Suraj Mudichintala | M | - |
Onc.ai, Inc.
Onc.ai, Inc. Packaged SoftwareTechnology Services Onc.ai, Inc. is a digital health company that is privately held and is developing a precision oncology care management platform. The company is based in San Carlos, CA. The company aims to transform clinical decision making and is backed by premier investment firms such as the Blue Venture Fund, MassMutual Alternative Investments, and Accomplice, among others. The company is building a pipeline of physician-centered products to fulfill the potential of precision oncology. The company was founded by Akshay Nanduri, who has been the CEO since incorporation. | - |
Tai-An Lin | M | 61 | 1 jaar | |
Juan-Pablo Mas | M | - |
Onc.ai, Inc.
Onc.ai, Inc. Packaged SoftwareTechnology Services Onc.ai, Inc. is a digital health company that is privately held and is developing a precision oncology care management platform. The company is based in San Carlos, CA. The company aims to transform clinical decision making and is backed by premier investment firms such as the Blue Venture Fund, MassMutual Alternative Investments, and Accomplice, among others. The company is building a pipeline of physician-centered products to fulfill the potential of precision oncology. The company was founded by Akshay Nanduri, who has been the CEO since incorporation. | 2 jaar |
Alison Milhous | F | 45 | - | |
Daniel Pichl | M | 41 | 4 jaar | |
Emir Sandhu | M | - |
Onc.ai, Inc.
Onc.ai, Inc. Packaged SoftwareTechnology Services Onc.ai, Inc. is a digital health company that is privately held and is developing a precision oncology care management platform. The company is based in San Carlos, CA. The company aims to transform clinical decision making and is backed by premier investment firms such as the Blue Venture Fund, MassMutual Alternative Investments, and Accomplice, among others. The company is building a pipeline of physician-centered products to fulfill the potential of precision oncology. The company was founded by Akshay Nanduri, who has been the CEO since incorporation. | 4 jaar |
Michael Nofi | M | 53 | 5 jaar | |
Matthew Jacobson | M | - |
The University of California, San Francisco
| 22 jaar |
Mark Smith | M | 72 |
The University of California, San Francisco
| 30 jaar |
David A. Kessler | M | 72 |
The University of California, San Francisco
| 21 jaar |
Ronald A. Krasnow | M | 61 |
Arch Oncology, Inc.
Arch Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA. | 4 jaar |
Bruce Keyt | M | 71 | 14 jaar | |
Pamela Palmer | M | 61 |
The University of California, San Francisco
| 28 jaar |
Craig David Gordon | M | - |
Gennao Bio, Inc.
Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021. | - |
Jonathan Fleming | M | 66 |
Onc.ai, Inc.
Onc.ai, Inc. Packaged SoftwareTechnology Services Onc.ai, Inc. is a digital health company that is privately held and is developing a precision oncology care management platform. The company is based in San Carlos, CA. The company aims to transform clinical decision making and is backed by premier investment firms such as the Blue Venture Fund, MassMutual Alternative Investments, and Accomplice, among others. The company is building a pipeline of physician-centered products to fulfill the potential of precision oncology. The company was founded by Akshay Nanduri, who has been the CEO since incorporation. | - |
Frank Perier | M | 64 | 5 jaar | |
Kristen Hege | M | 60 |
The University of California, San Francisco
| 28 jaar |
David Diaz-Casariego | M | - |
Onc.ai, Inc.
Onc.ai, Inc. Packaged SoftwareTechnology Services Onc.ai, Inc. is a digital health company that is privately held and is developing a precision oncology care management platform. The company is based in San Carlos, CA. The company aims to transform clinical decision making and is backed by premier investment firms such as the Blue Venture Fund, MassMutual Alternative Investments, and Accomplice, among others. The company is building a pipeline of physician-centered products to fulfill the potential of precision oncology. The company was founded by Akshay Nanduri, who has been the CEO since incorporation. | 1 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Stephen P. Squinto | M | 67 |
Gennao Bio, Inc.
Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021. | 6 jaar |
Lamberto Andreotti | M | 73 | 19 jaar | |
William Ringo | M | 78 | 7 jaar | |
Pascal Soriot | M | 64 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | - |
Sheila Gujrathi | M | 53 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 11 jaar |
Luis Borges | M | 62 | 5 jaar | |
Julie Cherrington | M | 66 |
Arch Oncology, Inc.
Arch Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA. | 3 jaar |
Michael Loberg | M | 76 | 8 jaar | |
Louis Lavigne | M | 75 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 23 jaar |
Ian Clark | M | 62 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 13 jaar |
John Tsai | M | 57 | 11 jaar | |
Daniel S. Chen | M | 55 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 15 jaar |
Anna L. Barry | M | - |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 8 jaar |
June Lee | M | 58 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 7 jaar |
L. Smith | M | 57 | 7 jaar | |
Lindsey Rolfe | M | 56 | 13 jaar | |
Jeffrey Schwartz | M | 45 | 6 jaar | |
Asha Das | M | 59 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 7 jaar |
Ryan Watts | M | 48 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 11 jaar |
S. Connelly | M | - |
The University of California, San Francisco
| 8 jaar |
Robert Steven Sikorski | M | - | 3 jaar | |
Robert Garnick | M | 74 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 24 jaar |
Alexander Hardy | M | 56 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | - |
Steven Hoerter | M | 53 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 11 jaar |
Kevin P. Baker | M | 63 | 12 jaar | |
Kapil Dhingra | M | 64 | 6 jaar | |
Douglas Manion | M | 64 | 11 jaar | |
Marc Tessier-Lavigne | M | 64 |
The University of California, San Francisco
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 19 jaar |
Markus Gemuend | M | - |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | - |
Brian Daniels | M | 65 | - | |
Myrtle Potter | F | 65 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 5 jaar |
Lewis B. Campbell | M | 77 | 18 jaar | |
Stephen G. Juelsgaard | M | 75 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 24 jaar |
Matthew Emmens | M | 72 | 4 jaar | |
Jeffrey Jones | M | 53 | 5 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 98 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Julie Hambleton
- Persoonlijk netwerk